Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi's sarcoma.

Cappelletti M, Taddeo A, Colombo E, Brambilla L, Bellinvia M, Pregliasco F, Villa ML, Della Bella S.

J Invest Dermatol. 2012 Oct;132(10):2414-2421. doi: 10.1038/jid.2012.151. Epub 2012 May 24.

2.

Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.

Zerbini CA, Ribeiro Dos Santos R, Jose Nunes M, Soni J, Li P, Jain VK, Ofori-Anyinam O.

Braz J Infect Dis. 2017 Jan - Feb;21(1):63-70. doi: 10.1016/j.bjid.2016.10.003. Epub 2016 Nov 29.

3.

Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.

PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.

4.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
5.

Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.

Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F.

Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20.

PMID:
22192847
6.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.

Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.

Vaccine. 2013 Nov 12;31(47):5572-8. doi: 10.1016/j.vaccine.2013.08.069. Epub 2013 Sep 7.

PMID:
24016810
7.

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.

Solares AR, Aragon CG, Pivaral RU, Prado-Cohrs D, Sales-Carmona V, Pellegrini M, Groth N.

J Infect Dev Ctries. 2014 Sep 12;8(9):1160-8. doi: 10.3855/jidc.4594.

8.

Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.

Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.

Vaccine. 2015 May 15;33(21):2485-92. doi: 10.1016/j.vaccine.2015.03.065. Epub 2015 Apr 2.

9.

Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.

Bai Y, Shi N, Lu Q, Yang L, Wang Z, Li L, Han H, Zheng D, Luo F, Zhang Z, Ai X.

Hum Vaccin Immunother. 2015;11(7):1648-53. doi: 10.1080/21645515.2015.1037998.

10.

A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.

Hum Vaccin Immunother. 2015;11(10):2370-5. doi: 10.1080/21645515.2015.1064570.

11.

Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.

Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Dramé M, Vaughn DW, Schuind A.

Vaccine. 2015 Jun 4;33(24):2800-7. doi: 10.1016/j.vaccine.2015.04.027. Epub 2015 Apr 21.

12.

Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial.

Bethell D, Saunders D, Jongkaewwattana A, Kramyu J, Thitithayanont A, Wiboon-ut S, Yongvanitchit K, Limsalakpetch A, Kum-Arb U, Uthaimongkol N, Garcia JM, Timmermans AE, Peiris M, Thomas S, Engering A, Jarman RG, Mongkolsirichaikul D, Mason C, Khemnu N, Tyner SD, Fukuda MM, Walsh DS, Pichyangkul S.

PLoS One. 2013;8(3):e59674. doi: 10.1371/journal.pone.0059674. Epub 2013 Mar 26.

13.

Effect of Antihelminthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial.

Brückner S, Agnandji ST, Berberich S, Bache E, Fernandes JF, Schweiger B, Massinga Loembe M, Engleitner T, Lell B, Mordmüller B, Adegnika AA, Yazdanbakhsh M, Kremsner PG, Esen M.

PLoS Negl Trop Dis. 2015 Jun 8;9(6):e0003768. doi: 10.1371/journal.pntd.0003768. eCollection 2015. Erratum in: PLoS Negl Trop Dis. 2015 Jun;9(6):e0003891.

14.

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.

Ansaldi F, Orsi A, de Florentiis D, Parodi V, Rappazzo E, Coppelli M, Durando P, Icardi G.

Hum Vaccin Immunother. 2013 Mar;9(3):591-8. Epub 2013 Jan 7.

15.

Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.

Tregnaghi MW, Stamboulian D, Vanadía PC, Tregnaghi JP, Calvari M, Fragapane E, Casula D, Pellegrini M, Groth N.

Viral Immunol. 2012 Jun;25(3):216-25. doi: 10.1089/vim.2011.0063.

PMID:
22691101
16.

Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma.

Della Bella S, Nicola S, Brambilla L, Riva A, Ferrucci S, Presicce P, Boneschi V, Berti E, Villa ML.

Clin Immunol. 2006 Jun;119(3):317-29. Epub 2006 Mar 9.

PMID:
16527545
17.

Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.

Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ.

Clin Vaccine Immunol. 2014 Jul;21(7):989-96. doi: 10.1128/CVI.00615-13. Epub 2014 May 14.

18.

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L, Treanor JJ.

BMC Infect Dis. 2010 Mar 17;10:71. doi: 10.1186/1471-2334-10-71.

19.

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.

Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Del Giudice G.

Hum Vaccin Immunother. 2012 Feb;8(2):216-27. doi: 10.4161/hv.18445. Epub 2012 Feb 1.

PMID:
22426371
20.

Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment.

Della Bella S, Taddeo A, Colombo E, Brambilla L, Bellinvia M, Pregliasco F, Cappelletti M, Calabrò ML, Villa ML.

PLoS One. 2010 Nov 29;5(11):e15029. doi: 10.1371/journal.pone.0015029.

Supplemental Content

Support Center